Biosignatures' technology has the potential to replace biopsies for cancer diagnosis with blood tests. Thank you for helping us to make this happen!
Participants in clinical trials
If you are participating in one of the studies Biosignatures is carrying out, thank you!
Biosignatures has developed a patented software system which it is using to create new diagnostic tests from the analysis of patient blood samples.
We simply could not do this without the expertise and skill of our clinical collaborators and the selfless support of patients.
Biosignatures are currently working with clinical partners on a range of research projects.
BiopSave Clinical Validation Trial, Freeman Hospital, Newcastle
This study is a blinded, prospective, non-randomised observational controlled study to validate the clinical performance of the BiopSave novel proteomic blood test for the diagnosis of prostate cancer. It compares the ability of the BiopSave assay to predict a biopsy-derived diagnosis of prostate cancer with that of current practice, which is based upon prostate specific antigen (PSA) level.
First results have come in, and it’s a success!
The product showed an 11.4% uplift compared to current practice.
Urology validation study, Sunderland Royal Hospital, Sunderland
This study has now been completed. Samples have been collected and used internally to test the performance of the prostate, bladder and renal signatures. Currently there are no results to report externally.
Urology discovery study, Freeman Hospital, Newcastle
This study has completed successfully. Four products have been discovered during the study in prostate, bladder and renal cancer. The first of two prostate products is being tested as described above.
Thyroid discovery study, Royal Victoria Infirmary, Newcastle
This study, which recently ceased recruitment having successfully reached its cohort target of 400 participants, is intended to discover candidate biomarkers which are capable of accurately predicting whether or not a patient has thyroid cancer, thereby aiding in both diagnosing new cases of the disease and monitoring of health of patients who have already undergone treatment. It is currently in the data-analysis phase.
Sunderland Royal Hospital
The company is currently involved in a major fundraising exercise and once this is complete will be looking to run multiple discovery projects and validation trials in sites in both the UK and the USA.
Biosignatures are therefore very interested in hearing from clinicians who have an interest in developing and validating new diagnostic and prognostic tools.
For example, in breast cancer a study is currently in the planning stage. Its objective is to discover novel biomarkers of breast cancer to enable invasive and time-consuming assays such as biopsies to be targeted towards women who are most likely to benefit from them.
In collaboration with AstraZeneca, Biosignatures' then parent company, Nonlinear Dynamics published the first study showing that gel-based proteomics combined with advanced software could reliably analyse human blood samples: Jackson, D. et al.(2009), Prot. Clin. Appl., 3: 394–407.
Novartis Institutes for BioMedical Research (NIBR)
With NIBR, Biosignatures ran a double blind trial of the Tiger discovery technology. In this trial, the the technology was able to identify the mode of action of antibiotics with 100% accuracy.
Working with some of the best laboratories in the field of proteomics and alongside NIBR, Biosignatures' then parent company, Nonlinear Dynamics ran the HUPO reproducibility study which proved for the first time 2D gels could generate data that was reproducible cross-lab.
Working with Bio-Rad, Biosignatures' then parent company, Nonlinear Dynamics led a follow-on reproducibility study which demonstrated how to use standards to enable labs to reproduce each others' work.
Feel free to get in touch about any aspect of Biosignatures and our range of products.